title: Predicting and evaluating response to omalizumab in patients with severe allergic asthma.
abstract: BACKGROUND
  Omalizumab is a monoclonal antibody indicated for treatment of severe persistent allergic asthma inadequately controlled despite optimal controller therapy. We investigated whether patient selection could be targeted further.
  
  
  METHODS
  Data from seven randomized controlled omalizumab trials were analyzed to investigate whether pre-treatment patient baseline clinical characteristics could be identified that were predictive of a superior response to omalizumab. We also studied whether patients who respond to omalizumab following a course of treatment could be reliably identified. Univariate/multivariate analyses of INNOVATE data were performed to identify predictive baseline measures and further investigated in efficacy analyses of pooled data from seven studies. The best method of identifying responders to omalizumab following treatment was determined by assessing the ability of various clinical response criteria to identify responders and discriminate patient exacerbation and other outcomes.
  
  
  RESULTS
  Baseline total immunoglobulin E (IgE) was the only predictor of efficacy in INNOVATE. However, pooled analysis showed treatment benefits irrespective of IgE levels. In omalizumab-treated patients, physician's overall assessment following a course of treatment identified 61% as responders and best discriminated treatment outcomes.
  
  
  CONCLUSIONS
  Baseline characteristics do not reliably predict benefit with omalizumab. Physician's overall assessment after 16 weeks of treatment is the most meaningful measure of response to therapy.
authors.affiliation: Service de Pneumologie, Hôpital Arnaud de Villeneuve, 371 Avenue du Doyen G Giraud, Montpellier 34295, France. jean.bousquet@wanadoo.fr
authors.forename: J
authors.initials: J
authors.lastname: Bousquet
authors.forename: K
authors.initials: K
authors.lastname: Rabe
authors.forename: M
authors.initials: M
authors.lastname: Humbert
authors.forename: K F
authors.initials: KF
authors.lastname: Chung
authors.forename: W
authors.initials: W
authors.lastname: Berger
authors.forename: H
authors.initials: H
authors.lastname: Fox
authors.forename: G
authors.initials: G
authors.lastname: Ayre
authors.forename: H
authors.initials: H
authors.lastname: Chen
authors.forename: K
authors.initials: K
authors.lastname: Thomas
authors.forename: M
authors.initials: M
authors.lastname: Blogg
authors.forename: S
authors.initials: S
authors.lastname: Holgate
mesh_terms: D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D005541:Forced Expiratory Volume; D006305:Health Status Indicators; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D000069444:Omalizumab; D018579:Patient Selection; D011379:Prognosis; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E